Form 4: OptimizeRx COO Merrell Reports Equity Grants & Tax Sales
Insider Transaction Report
OptimizeRx Chief Operating Officer Brendan W. Merrell reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax obligations.
Summary
- Chief Operating Officer Brendan W. Merrell acquired 10,417 restricted stock units (RSUs) on August 21, 2025.
- These RSUs will vest in three equal annual installments beginning on August 21, 2026.
- Merrell also acquired 23,437 stock options on August 21, 2025, with an exercise price of $16.14.
- These stock options will vest in three equal annual installments starting August 21, 2026, and have an expiration date of August 21, 2030.
- On October 3, 2025, 483 shares were disposed of at a price of $18.75 per share to satisfy tax withholding obligations.
- Following these reported transactions, Merrell beneficially owns 27,208 shares of common stock and 46,874 stock options.
Sentiment
Score: 6
Explanation: The filing details routine executive equity compensation and tax-related share dispositions, which are standard corporate practices and generally viewed as neutral to slightly positive as they align executive interests with shareholders.
Positives
- The grant of restricted stock units and stock options aligns the Chief Operating Officer's interests with those of shareholders, incentivizing long-term company performance.
Negatives
- The disposition of 483 shares was solely for tax withholding purposes, a routine event, and does not indicate a negative outlook on the company.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Grant of 10,417 restricted stock units and 23,437 stock options to Chief Operating Officer Brendan W. Merrell as part of executive compensation.
Stakeholder Impact
- Shareholders: The equity grants to the COO enhance alignment between executive incentives and shareholder interests, potentially fostering long-term value creation.
- Employees: These transactions reflect standard executive compensation practices within the company.
Next Steps
- Vesting of restricted stock units and stock options in three equal annual installments beginning August 21, 2026.
Key Dates
| Date | Description |
|---|---|
| 08/21/2025 | Grant date for 10,417 Restricted Stock Units (RSUs) and 23,437 Stock Options to Brendan W. Merrell. |
| 10/03/2025 | Date of disposition of 483 shares to satisfy tax withholding obligations. |
| 08/21/2026 | First anniversary of the grant date, marking the beginning of the three equal annual vesting installments for both RSUs and Stock Options. |
| 08/21/2030 | Expiration date for the granted stock options. |
Recommendation
holdThis Form 4 filing details routine equity grants and tax-related dispositions for a company executive. While it shows continued alignment of management interests with shareholders through equity ownership, it does not contain information significant enough to alter an investment thesis or warrant a change in recommendation based solely on this disclosure.
Keywords
OptimizeRx, OPRX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.